Therapeutic efficacy of antiglioma mesenchymal extracellular matrix super(131)I-radiolabeled murine monoclonal antibody in a human glioma xenograft model

• Published in: Cancer research (Chicago, Ill.) Vol. 48; no. 3; pp. 559 - 566
• Main Authors: Lee, Yi-Sheng, Bullard, DE, Zalutsky, M R, Coleman, R E, Wikstrand, C J, Friedmann, H S, Colapinto, E V, Bigner, D D
• Format: Journal Article
• Language: English
• Published: 01.01.1988
• ISSN: 0008-5472

The development of Mabs, particularly those reactive with primary brain tumors but not with normal brain, provides a potential means of delivering therapeutic agents selectively to human malignant gliomas. Mab 81C6, an IgG2b immunoglobulin, which defines an epitope of the glioma-associated extracellular matrix protein tenascin, has been shown to bind to human glioma cell lines, glioma xenografts in nude mice, and primary human gliomas, but not to normal adult or fetal brain. To test the therapeutic potential of this Mab for targeted delivery of isotopes, nude mice bearing progressively growing s.c. xenografts of D-54 MG, a human glioma cell line, were given injections via the tail vein of either buffer, unlabeled 81C6, super(131)I-labeled 81C6, or super(131)I-labeled 45.6, a nonspecific control Mab of the same isotype.